Singapore
[MARKET·SG]Regulator: Health Sciences Authority
prescriptive
direct-to-practitioner
Decoded engages with brands through the Decoded Entry Protocol — a six-stage framework covering inbound brief, mutual diligence, commercial framework, regulatory and channel preparation, and committed launch and stewardship across the six principal Southeast Asian markets.
Premium is preserved through channel discipline and dossier completeness — not asserted in copy. The firm declines work it cannot defend at premium positioning across the bloc.
SG, MY, ID, TH, VN, PH — operated under one documentation regime and one regulatory cadence so a launch in one is the launch design for the others.
Notification and registration dossiers built once and maintained per market. Halal posture decided at formulation, not retrofitted at audit.
Channel discipline, pricing posture, and post-market obligations operated against a single internal record — published to principals on request.
Every brand engagement runs the same protocol — start to finish — so both sides know where the relationship is at every point. Refusal is part of the work, and most engagements end at stage 2 with a written reason.
Brand owner submits a structured brief — origin, category, certifications, target markets, current footprint, and the specific Southeast Asian thesis.
The firm assesses category fit, regulatory feasibility, and channel coherence against an internal rubric. Most relationships end here, with a written reason.
Under NDA: dossier review on the brand side, governance disclosure on the firm side. Either party may close the file at any point.
Term sheet covering territory grants, exclusivity, regulatory ownership, marketing approval rights, and the specific quality and pharmacovigilance commitments.
Notification dossiers filed in the agreed launch markets; channel partners briefed; first-shipment forecast and quality plan committed in writing.
First market goes live; the firm publishes a brand record (regulatory status, channel set, post-market obligations) and operates against it across the contract term.
Each market has its own regulator, channel structure, and posture — but the documentation discipline Decoded applies is the same across the bloc.
Regulator: Health Sciences Authority
prescriptive
direct-to-practitioner
Regulator: National Pharmaceutical Regulatory Agency (NPRA)
permissive-with-documentation
clinic-network
Regulator: BPOM (Balai Pengawas Obat dan Makanan)
narrative-required
distributor-led
Regulator: Thai FDA (Food and Drug Administration, Ministry of Public Health)
prescriptive-hybrid
clinic-and-hospital
Regulator: Drug Administration of Vietnam
tightening
hospital-pharmacy
Regulator: Bureau of Food and Drugs (BFAD)
narrative-required
clinic-pharmacy-retail
Regulator: South African Health Products Regulatory Authority (SAHPRA)
prescriptive
clinic-and-retail
Regulator: Medicines Regulatory Authority of Botswana (MRAB)
streamlined
clinic-pharmacy
Regulator: Ministry of Health & Social Services (MHSS) / Namibia Medicines Regulatory Council
streamlined
clinic-pharmacy
Regulator: Medicines Control Authority of Zimbabwe (MCAZ)
permissive
distributor-led
Manufacturing site holding category-appropriate certification (PIC/S GMP, ISO 22716, ISO 13485, HACCP, ISO 22000) with current third-party audits.
Existing footing in at least one demanding regulator (EU, US FDA, TGA, Health Canada, MFDS, PMDA) — or a credible plan to land one.
Pricing architecture that survives a Singapore-anchored launch into Indonesia, Thailand, and the Philippines without collapse.
Founding leadership that treats regulatory and pharmacovigilance commitments as first-order, not handle-later.
A specific Southeast Asian thesis — not 'global brand looking for distributors'.
A written first-pass review from the firm — including a refusal, when refusal is the honest answer.
Mutual NDA before any technical or commercial dossier crosses either way.
A term sheet that names the regulatory owner, the commercial framework, and the quality and pharmacovigilance commitments.
Notification dossiers filed in the agreed launch markets on the agreed timeline — or a written explanation if the timeline shifts.
A brand record published internally and shared on request — covering regulatory status, channel set, and post-market obligations.
Pick a category and the markets in scope. The firm's tool returns a deterministic per-market scaffold — what the regulator is, what posture the category sits under, and which obligations bind first.
// select a category and at least one market, then run.
output renders the firm's deterministic regulatory scaffold per market.
A five-question screen the firm runs internally before Stage 02. Answer in one sitting; the tool returns a heuristic fit score and the two dimensions that decide whether a brief proceeds.
Decoded engages with brands that hold category-appropriate manufacturing certification, an existing footing in at least one demanding regulator, and a pricing architecture that survives a Singapore-anchored launch into the rest of the bloc. Stage in years matters less than that posture being already in place.
The first-pass written review lands within fourteen working days of an inbound brief. Mutual diligence and the term sheet typically run six to ten weeks. Regulatory and channel preparation runs in parallel with notification dossier work; the timeline is decided per market and is named in the term sheet, not implied.
Singapore, Malaysia, Indonesia, Thailand, Vietnam, and the Philippines — operated under one documentation regime so a launch in one market is the launch design for the others. The firm does not represent brands outside ASEAN and does not operate in markets it cannot file in.
Pricing architecture that cannot survive the bloc, missing third-party manufacturing audits, an active-ingredient profile that the firm cannot defend in front of HSA or BPOM, or a 'global brand looking for distributors' posture without a specific Southeast Asian thesis. Refusal at Stage 02 is part of the work and is delivered in writing.
No. Commercial framework, contract template, and post-market obligations are released to brand leadership under NDA via the Partner Prospectus. Pricing is not a marketing surface and is not implied by any tool output, simulator, or assessment on this site.
A structured submission lands as Stage 01 of the Entry Protocol. The firm acknowledges every inbound brief and returns a written first-pass review — including a refusal, when refusal is the honest answer. The form interface lands in STEP 6; the inbox is live today.
Email a partner briefA working document covering the firm's mandate, regulatory posture per market, channel philosophy, and the standing contract template. Released on request to brand leadership under NDA.
Request the Prospectus